This concept may be disputed considering that in many studies, the dose of omalizumab used was low compared with the markedly elevated patient IgE levels, the small and heterogeneous populations studied, and the evidence that IgE seems to play a significant role in majority of AD patients with IgE targeting treatments showing efficacy. The gene discussed is IGHE; the disease is Alzheimer disease.